Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2015 | Research

CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma

Authors: Ting Li, Yingying Cheng, Pingzhang Wang, Wenyan Wang, Fengzhan Hu, Xiaoning Mo, Hongxia Lv, Tao Xu, Wenling Han

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2015

Abstract

Background

Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM) is a gene family involved in multiple malignancies. CMTM4 is a member of this family and is located at chromosome 16q22.1, a locus that harbours a number of tumour suppressor genes. It has been defined as a regulator of cell cycle and division in HeLa cells; however, its roles in tumourigenesis remain poorly studied.

Methods

An integrated bioinformatics analysis based on the array data from the GEO database was conducted to view the differential expression of CMTM4 across multiple cancers and their corresponding control tissues. Primary clear cell renal cell carcinoma (ccRCC) and the paired adjacent non-tumour tissues were then collected to examine the expression of CMTM4 by western blotting, immunohistochemistry, and quantitative RT-PCR. The ccRCC cell lines A498 and 786-O and the normal renal tubular epithelial cell line HK-2 were also tested for CMTM4 expression by western blotting. Cell Counting Kit-8 (CCK-8) and viable cell counting assays were used to delineate the growth curves of 786-O cells after CMTM4 overexpression or knockdown. Wound healing and transwell assays were performed to assess the cells’ ability to migrate. The effects of CMTM4 on cellular apoptosis and cell cycle progression were analysed by flow cytometry, and cell cycle hallmarks were detected by western blotting and RT-PCR. The xenograft model in nude mice was used to elucidate the function of CMTM4 in tumourigenesis ex vivo.

Results

By omic data analysis, we found a substantial downregulation of CMTM4 in ccRCC. Western blotting then confirmed that CMTM4 was dramatically reduced in 86.9 % (53/61) of ccRCC tissues compared with the paired adjacent non-tumour tissues, as well as in the 786-O and A498 ccRCC cell lines. Restoration of CMTM4 significantly suppressed 786-O cell growth by inducing G2/M cell cycle arrest and p21 upregulation, and cell migration was also inhibited. However, knockdown of CMTM4 led to a completely opposite effect on these cell behaviours. Overexpression of CMTM4 also markedly inhibited the tumour xenograft growth in nude mice.

Conclusions

CMTM4 is downregulated and exhibits tumour-suppressor activities in ccRCC, and could be exploited as a target for ccRCC treatment.

Busch J, Ralla B, Jung M, Wotschofsky Z, Trujillo-Arribas E, Schwabe P, et al. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J Exp Clin Cancer Res. 2015;34:61.PubMedCentralCrossRefPubMed

Zhuang J, Tu X, Cao K, Guo S, Mao X, Pan J, et al. The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma. J Exp Clin Cancer Res. 2014;33:25.PubMedCentralCrossRefPubMed

Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183:1309–15.CrossRefPubMed

Grimm MO, Wolff I, Zastrow S, Frohner M, Wirth M. Advances in renal cell carcinoma treatment. Ther Adv Urol. 2010;2:11–7.PubMedCentralPubMed

Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y, et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J. 2001;357:127–35.PubMedCentralCrossRefPubMed

Han W, Ding P, Xu M, Wang L, Rui M, Shi S, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics. 2003;81:609–17.CrossRefPubMed

Chowdhury MH, Nagai A, Terashima M, Sheikh A, Murakawa Y, Kobayashi S, et al. Chemokine-like factor expression in the idiopathic inflammatory myopathies. Acta Neurol Scand. 2008;118:106–14.CrossRefPubMed

Tian L, Li W, Wang J, Zhang Y, Zheng Y, Qi H, et al. The CKLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma. Allergy. 2011;66:287–97.CrossRefPubMed

Zheng Y, Guo C, Zhang Y, Qi H, Sun Q, Xu E, et al. Alleviation of murine allergic rhinitis by C19, a C-terminal peptide of chemokine-like factor 1 (CKLF1). Int Immunopharmacol. 2011;11:2188–93.CrossRefPubMed

10.

Tan Y, Wang Y, Li L, Xia J, Peng S, He Y. Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis. PLoS One. 2015;10:e0125073.PubMedCentralCrossRefPubMed

11.

Miyazaki A, Yogosawa S, Murakami A, Kitamura D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS One. 2012;7:e31829.PubMedCentralCrossRefPubMed

12.

Shi S, Rui M, Han W, Wang Y, Qiu X, Ding P, et al. CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules. Int J Biochem Cell Biol. 2005;37:1633–40.CrossRefPubMed

13.

Liu G, Xin ZC, Chen L, Tian L, Yuan YM, Song WD, et al. Expression and localization of CKLFSF2 in human spermatogenesis. Asian J Androl. 2007;9:189–98.CrossRefPubMed

14.

Wang Y, Li T, Qiu X, Mo X, Zhang Y, Song Q, et al. CMTM3 can affect the transcription activity of androgen receptor and inhibit the expression level of PSA in LNCaP cells. Biochem Biophys Res Commun. 2008;371:54–8.CrossRefPubMed

15.

Jin C, Ding P, Wang Y, Ma D. Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett. 2005;579:6375–82.CrossRefPubMed

16.

Shao L, Cui Y, Li H, Liu Y, Zhao H, Wang Y, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res. 2007;13:5756–62.CrossRefPubMed

17.

Shao L, Guo X, Plate M, Li T, Wang Y, Ma D, et al. CMTM5-v1 induces apoptosis in cervical carcinoma cells. Biochem Biophys Res Commun. 2009;379:866–71.CrossRefPubMed

18.

Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009;69:5194–201.CrossRefPubMed

19.

Guo X, Li T, Wang Y, Shao L, Zhang Y, Ma D, et al. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha. Biochem Biophys Res Commun. 2009;387:139–42.CrossRefPubMed

20.

Li P, Liu K, Li L, Yang M, Gao W, Feng J, et al. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:1248–55.PubMed

21.

Su Y, Lin Y, Zhang L, Liu B, Yuan W, Mo X, et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci. 2014;105:26–34.PubMedCentralCrossRefPubMed

22.

Zhang H, Nan X, Li X, Chen Y, Zhang J, Sun L, et al. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma. Biochem Biophys Res Commun. 2014;447:304–10.CrossRefPubMed

23.

Li H, Li J, Su Y, Fan Y, Guo X, Li L, et al. A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. Oncogene. 2014;33:3109–18.CrossRefPubMed

24.

Both J, Krijgsman O, Bras J, Schaap GR, Baas F, Ylstra B, et al. Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma. PLoS One. 2014;9:e115835.PubMedCentralCrossRefPubMed

25.

Delic S, Thuy A, Schulze M, Proescholdt MA, Dietrich P, Bosserhoff AK, et al. Systematic investigation of CMTM family genes suggests relevance to glioblastoma pathogenesis and CMTM1 and CMTM3 as priority targets. Genes Chromosomes Cancer. 2015;54:433–43.CrossRefPubMed

26.

Downing TE, Oktay MH, Fazzari MJ, Montagna C. Prognostic and predictive value of 16p12.1 and 16q22.1 copy number changes in human breast cancer. Cancer Genet Cytogenet. 2010;198:52–61.CrossRefPubMed

27.

Keck B, Ellmann C, Stoehr R, Weigelt K, Goebell PJ, Kunath F, et al. Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma. Urol Oncol. 2014;32:1234–9.CrossRefPubMed

28.

Sun Q, Yang YM, Yu SH, Zhang YX, He XG, Sun SS, et al. Covariation of copy number located at 16q22.1: new evidence in mammary ductal carcinoma. Oncol Rep. 2012;28:2156–62.PubMed

29.

Fu L, Dong SS, Xie YW, Tai LS, Chen L, Kong KL, et al. Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma. Hepatology. 2010;51:1624–34.CrossRefPubMed

30.

Costa AR, Vasudevan A, Krepischi A, Rosenberg C, Chauffaille ML. Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia. Med Oncol. 2013;30:579.CrossRefPubMed

31.

Czarnecka KH, Migdalska-Sek M, Antczak A, Pastuszak-Lewandoska D, Kordiak J, Nawrot E, et al. Allelic imbalance in 1p, 7q, 9p, 11p, 12q and 16q regions in non-small cell lung carcinoma and its clinical association: a pilot study. Mol Biol Rep. 2013;40:6671–84.PubMedCentralCrossRefPubMed

32.

Brys M, Migdalska-Sek M, Pastuszak-Lewandoska D, Forma E, Czarnecka K, Domanska D, et al. Diagnostic value of DNA alteration: loss of heterozygosity or allelic imbalance-promising for molecular staging of prostate cancers. Med Oncol. 2013;30:391.PubMedCentralCrossRefPubMed

33.

Czarnecka K, Pastuszak-Lewandoska D, Migdalska-Sek M, Nawrot E, Brzezinski J, Dedecjus M, et al. Aberrant methylation as a main mechanism of TSGs silencing in PTC. Front Biosci (Elite Ed). 2011;3:137–57.CrossRef

34.

Plate M, Li T, Wang Y, Mo X, Zhang Y, Ma D, et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through Inducing G2/M phase accumulation. Mol Cells. 2010;29:355–61.CrossRefPubMed

35.

Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature. 2004;432:1036–40.CrossRefPubMed

36.

Wang P, Qi H, Song S, Li S, Huang N, Han W, et al. ImmuCo: a database of gene co-expression in immune cells. Nucleic Acids Res. 2015;43:D1133–9.PubMedCentralCrossRefPubMed

37.

Wang P, Yang Y, Han W, Ma D. ImmuSort, a database on gene plasticity and electronic sorting for immune cells. Sci Rep. 2015;5:10370.PubMedCentralCrossRefPubMed

38.

Li T, Guo X, Wang Y, Plate M, Shao L, Song Q, et al. Preparation, purification and characterization of the polyclonal antibody against human CMTM4. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2008;24:41–4.PubMed

39.

Ji SQ, Yao L, Zhang XY, Li XS, Zhou LQ. Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cellcarcinoma cells in vitro and in vivo. J Exp Clin Cancer Res. 2012;31:22.PubMedCentralCrossRefPubMed

40.

Wan Q, Dingerdissen H, Fan Y, Gulzar N, Pan Y, Wu TJ, et al. BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis. Database (Oxford). 2015; doi: 10.1093/database/bav019.

41.

Cmielova J, Rezacova M. p21Cip1/Waf1 protein and its function based on a subcellular localization [corrected]. J Cell Biochem. 2011;112:3502–6.CrossRefPubMed

42.

Weinberg WC, Denning MF. P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med. 2002;13:453–64.CrossRefPubMed

43.

Ishimaru T, Lau J, Jackson AL, Modiano JF, Weiss RH. Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma. J Urol. 2010;184:2143–9.CrossRefPubMed

Title: CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
Authors: Ting Li
Yingying Cheng
Pingzhang Wang
Wenyan Wang
Fengzhan Hu
Xiaoning Mo
Hongxia Lv
Tao Xu
Wenling Han
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2015
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-015-0236-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Hypoxia-inducible MiR-182 promotes angiogenesis by targeting RASA1 in hepatocellular carcinoma

Small nucleolar RNA 78 promotes the tumorigenesis in non-small cell lung cancer

The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR–155–Rb1 pathway

Dual-targeting of aberrant glucose metabolism in glioblastoma

ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis

A fresh look at zebrafish from the perspective of cancer research

Keynote webinar | Spotlight on antibody–drug conjugates in cancer